#USA #Cambrex #East Rutherford #Snapdragon Chemistry #Q1 Scientific

Cambrex Leads the Charge in Sustainable Pharmaceutical Practices

In recent news, Cambrex, a prominent player in the contract development and manufacturing organization (CDMO) sector, has made headlines for its commitment to innovation and sustainability in pharmaceuticals. This initiative is highlighted by the recognition received from the American Chemical Society (ACS), awarding a Green Chemistry Challenge Award in 2026 to Snapdragon Chemistry, a subsidiary of Cambrex. This acknowledgment pertains to the development of a sustainable synthetic route for the production of pharmaceutical products, marking a notable achievement in the industry.

The Award-Winning Process

The prize celebrates a cutting-edge organocatalytic process developed collaboratively with NewAmsterdam Pharma for the synthesis of the chiral core of tetrahydroquinoline, used in the advanced research therapy obicetrapib, aimed at addressing dyslipidemia. This new method showcases significant improvements over previous manufacturing routes by enhancing overall efficiency and sustainability. Critical metrics indicate an approximately 80% reduction in mass intensity, virtually eliminating aqueous waste, and shortening manufacturing cycle times by about 70%. Moreover, manufacturing costs have decreased by roughly 50%, demonstrating substantial financial and environmental benefits.

A Commitment to Sustainability

Cambrex's plant in Milan recently received a Gold rating from EcoVadis, positioning it among the top 5% of organizations based on environmental, social, and ethical performance. This accolade not only signifies the company’s robust sustainability strategies, including a 20% reduction in greenhouse gas emissions across its network, but also highlights its ambitious target to achieve a 50% reduction by 2030.

In another effort to bolster its sustainable initiatives, Q1 Scientific, another entity under the Cambrex umbrella, has partnered with Flogas through a Corporate Power Purchase Agreement (CPPA). This partnership aims to procure renewable electricity from the Cronalaght wind farm, thereby supplying about 50% of the energy demand for Q1’s Waterford facility. This initiative aligns with both consumer and community environmental goals, further solidifying Cambrex’s position as a responsible leader in the pharmaceutical landscape.

The Future of Pharmaceutical Innovation

Thomas Loewald, CEO of Cambrex, emphasized the company’s dedication to continually mitigating its environmental impact while ensuring long-term sustainable manufacturing solutions for customers. As the pharmaceutical sector moves toward more eco-friendly practices, Cambrex is setting industry standards for sustainability, showcasing that innovative thinking can lead to practical solutions that benefit both the environment and business efficiency.

As pharmaceutical companies face increased pressure to adopt environmentally sustainable practices, Cambrex, along with its subsidiaries Snapdragon Chemistry and Q1 Scientific, exemplifies what can be achieved through commitment to innovation and responsibility. Their recent accolades and developments serve as a guiding light for others in the industry, illustrating that success and sustainability can go hand in hand in crafting the future of pharmaceuticals.

With over 45 years of experience, Cambrex continues to offer specialized services in active pharmaceutical ingredient (API) development and manufacturing, employing a team of 2,000 experts across North America and Europe. Their expertise spans various domains, including continuous flow technology, stringent control of substances, peptide synthesis, solid-state science, and complex synthesis techniques. Cambrex’s integrated approach to service ensures that advanced methodologies are at the forefront of drug development, all while maintaining an unwavering commitment to sustainability.